Switching to Single-Pill Regimen Controls HIV as Well as Other Standard Treatment
PROF.DRRAM ,HIV/AIDS,SEX Diseases, Hepatitis .& Deaddiction
profdrram@gmail.com,+917838059592,+919832025033,,INDIA
HIV/ AIDS,HEPATITIS,MODERN MEDICINES AT CHEAP RATE.
FOLLOW ON FACE BOOK:www.facebook.com/profdrram

New data show equal control of HIV levels when switching from a standard multi-pill regimen to the single-tablet regimen of Triumeq (dolutegravir + abacavir + lamivudine).
The STRIIVING study presented 48-week data on switching to Triumeq from various other regimens in people currently on treatment with controlled viral loads. The Phase 3 study divided 553 people into two groups: the first switched immediately at study start to Triumeq while the other group switched after 24 weeks on their current regimen.
After the first 24 weeks, 85% of the early switch group vs. 88% who stayed on their regimens had undetectable viral loads <400 copies. After 48 weeks, 83% of the early switch group stayed undetectable. In the late switch group, 92% were undetectable after 24 weeks of their switch.
Side effects reported most often were nausea, diarrhea, upper respiratory infection, tiredness and headache. The rate of side effects was 21% within the first 24 weeks of the early switch group and then 22% for their second 24 weeks. The rate was 13% over 24 weeks for the late switch group.
No participant in either group had virologic failure. Ten people in the early switch group stopped the study by week 24 due to side effects, although no one else in that group quit in the second 24 weeks. Four people in the late switch group stopped after their switch.